United States - English - NLM (National Library of Medicine)

general injectables & vaccines, inc - midazolam hydrochloride (unii: w7ttw573jj) (midazolam - unii:r60l0sm5bc) - midazolam 5 mg in 1 ml - midazolam injection is indicated: - intramuscularly or intravenously for preoperative sedation/anxiolysis/amnesia; - intravenously as an agent for sedation/anxiolysis/amnesia prior to or during diagnostic, therapeutic or endoscopic procedures, such as bronchoscopy, gastroscopy, cystoscopy, coronary angiography, cardiac catheterization, oncology procedures, radiologic procedures, suture of lacerations and other procedures either alone or in combination with other cns depressants; - intravenously for induction of general anesthesia, before administration of other anesthetic agents. with the use of narcotic premedication, induction of anesthesia can be attained within a relatively narrow dose range and in a short period of time. intravenous midazolam can also be used as a component of intravenous supplementation of nitrous oxide and oxygen (balanced anesthesia); - continuous intravenous infusion for sedation of intubated and mechanically ventilated patients as a component of anesthesia or during treatment in a c

United States - English - NLM (National Library of Medicine)

cardinal health - midazolam hydrochloride (unii: w7ttw573jj) (midazolam - unii:r60l0sm5bc) - midazolam injection is indicated: injectable midazolam is contraindicated in patients with a known hypersensitivity to the drug. benzodiazepines are contraindicated in patients with acute narrow-angle glaucoma. benzodiazepines may be used in patients with open-angle glaucoma only if they are receiving appropriate therapy. measurements of intraocular pressure in patients without eye disease show a moderate lowering following induction with midazolam; patients with glaucoma have not been studied. midazolam is subject to schedule iv control under the controlled substances act of 1970. midazolam was actively self-administered in primate models used to assess the positive reinforcing effects of psychoactive drugs. midazolam produced physical dependence of a mild to moderate intensity in cynomolgus monkeys after 5 to 10 weeks of administration. available data concerning the drug abuse and dependence potential of midazolam suggest that its abuse potential is at least equivalent to that of diazepam. withdrawal sympto

United States - English - NLM (National Library of Medicine)

dispensing solutions, inc. - midazolam hydrochloride (unii: w7ttw573jj) (midazolam - unii:r60l0sm5bc) - midazolam hydrochloride 5 mg in 1 ml - midazolam injection is indicated: - intramuscularly or intravenously for preoperative sedation/anxiolysis/amnesia; intramuscularly or intravenously for preoperative sedation/anxiolysis/amnesia; - intravenously as an agent for sedation/anxiolysis/amnesia prior to or during diagnostic, therapeutic or endoscopic procedures, such as bronchoscopy, gastroscopy, cystoscopy, coronary angiography, cardiac catheterization, oncology procedures, radiologic procedures, suture of lacerations and other procedures either alone or in combination with other cns depressants; intravenously as an agent for sedation/anxiolysis/amnesia prior to or during diagnostic, therapeutic or endoscopic procedures, such as bronchoscopy, gastroscopy, cystoscopy, coronary angiography, cardiac catheterization, oncology procedures, radiologic procedures, suture of lacerations and other procedures either alone or in combination with other cns depressants; - intravenously for induction of general anesthesia, before administration of other anes

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - midazolam, quantity: 50 mg - injection, solution - excipient ingredients: sodium chloride; water for injections; hydrochloric acid; sodium hydroxide - intravenously (iv) as an agent for: . - conscious sedation prior to short surgical, diagnostic, therapeutic or endoscopic procedures such as bronchoscopy, gastroscopy, cystoscopy, coronary angiography and cardiac catheterisation, either alone or in conjunction with an opioid . - induction of anaesthesia preliminary to administration of other anaesthetic agents. with the use of an opioid premedicant, induction of anaesthesia can be attained with a narrower dose range and in a shorter period of time. .,intermittent iv administration or continuous infusion for: . - sedation in intensive care units, intermittent administration or continuous infusion.,intramuscularly (im) for: . - preoperative sedation (induction of sleepiness or drowsiness and relief of apprehension) and to impair memory of perioperative events

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - midazolam, quantity: 5 mg - injection, solution - excipient ingredients: sodium hydroxide; hydrochloric acid; water for injections; sodium chloride - intravenously (iv) as an agent for: . - conscious sedation prior to short surgical, diagnostic, therapeutic or endoscopic procedures such as bronchoscopy, gastroscopy, cystoscopy, coronary angiography and cardiac catheterisation, either alone or in conjunction with an opioid . - induction of anaesthesia preliminary to administration of other anaesthetic agents. with the use of an opioid premedicant, induction of anaesthesia can be attained with a narrower dose range and in a shorter period of time. .,intermittent iv administration or continuous infusion for: . - sedation in intensive care units, intermittent administration or continuous infusion.,intramuscularly (im) for: . - preoperative sedation (induction of sleepiness or drowsiness and relief of apprehension) and to impair memory of perioperative events

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - midazolam, quantity: 5 mg - injection, solution - excipient ingredients: water for injections; sodium chloride; sodium hydroxide; hydrochloric acid - intravenously (iv) as an agent for: . - conscious sedation prior to short surgical, diagnostic, therapeutic or endoscopic procedures such as bronchoscopy, gastroscopy, cystoscopy, coronary angiography and cardiac catheterisation, either alone or in conjunction with an opioid . - induction of anaesthesia preliminary to administration of other anaesthetic agents. with the use of an opioid premedicant, induction of anaesthesia can be attained with a narrower dose range and in a shorter period of time. .,intermittent iv administration or continuous infusion for: . - sedation in intensive care units, intermittent administration or continuous infusion.,intramuscularly (im) for: . - preoperative sedation (induction of sleepiness or drowsiness and relief of apprehension) and to impair memory of perioperative events

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - midazolam, quantity: 15 mg - injection, solution - excipient ingredients: water for injections; hydrochloric acid; sodium hydroxide; sodium chloride - intravenously (iv) as an agent for: . - conscious sedation prior to short surgical, diagnostic, therapeutic or endoscopic procedures such as bronchoscopy, gastroscopy, cystoscopy, coronary angiography and cardiac catheterisation, either alone or in conjunction with an opioid . - induction of anaesthesia preliminary to administration of other anaesthetic agents. with the use of an opioid premedicant, induction of anaesthesia can be attained with a narrower dose range and in a shorter period of time. .,intermittent iv administration or continuous infusion for: . - sedation in intensive care units, intermittent administration or continuous infusion.,intramuscularly (im) for: . - preoperative sedation (induction of sleepiness or drowsiness and relief of apprehension) and to impair memory of perioperative events

United States - English - NLM (National Library of Medicine)

wockhardt usa llc. - midazolam hydrochloride (unii: w7ttw573jj) (midazolam - unii:r60l0sm5bc) - midazolam 1 mg in 1 ml - midazolam hydrochloride injection, usp is indicated: - intramuscularly or intravenously for preoperative sedation/anxiolysis/amnesia; - intravenously as an agent for sedation/anxiolysis/amnesia prior to or during diagnostic, therapeutic or endoscopic procedures, such as bronchoscopy, gastroscopy, cystoscopy, coronary angiography, cardiac catheterization, oncology procedures, radiologic procedures, suture of lacerations and other procedures either alone or in combination with other cns depressants; - intravenously for induction of general anesthesia, before administration of other anesthetic agents. with the use of narcotic premedication, induction of anesthesia can be attained within a relatively narrow dose range and in a short period of time. intravenous midazolam hydrochloride can also be used as a component of intravenous supplementation of nitrous oxide and oxygen (balanced anesthesia); - continuous intravenous infusion for sedation of intubated

United States - English - NLM (National Library of Medicine)

gland pharma limited - midazolam hydrochloride (unii: w7ttw573jj) (midazolam - unii:r60l0sm5bc) - midazolam 5 mg in 1 ml - midazolam injection is indicated: •  intramuscularly or intravenously for preoperative sedation/anxiolysis/amnesia; •  intravenously as an agent for sedation/anxiolysis/amnesia prior to or during diagnostic, therapeutic or endoscopic procedures, such as bronchoscopy, gastroscopy, cystoscopy, coronary angiography, cardiac catheterization, oncology procedures, radiologic procedures, suture of lacerations and other procedures either alone or in combination with other cns depressants; •  intravenously for induction of general anesthesia, before administration of other anesthetic agents. with the use of narcotic premedication, induction of anesthesia can be attained within a relatively narrow dose range and in a short period of time. intravenous midazolam can also be used as a component of intravenous supplementation of nitrous oxide and oxygen (balanced anesthesia); •  continuous intravenous infusion for sedation of intubated and mechanically ventilated patients as a component of anesthesia or during tr

United States - English - NLM (National Library of Medicine)

athenex pharmaceutical division, llc. - midazolam hydrochloride (unii: w7ttw573jj) (midazolam - unii:r60l0sm5bc) - midazolam injection, usp is indicated: - intramuscularly or intravenously for preoperative sedation/anxiolysis/amnesia; - intravenously as an agent for sedation/anxiolysis/amnesia prior to or during diagnostic, therapeutic or endoscopic procedures, such as bronchoscopy, gastroscopy, cystoscopy, coronary angiography, cardiac catheterization, oncology procedures, radiologic procedures, suture of lacerations and other procedures either alone or in combination with other cns depressants; - intravenously for induction of general anesthesia, before administration of other anesthetic agents. with the use of narcotic premedication, induction of anesthesia can be attained within a relatively narrow dose range and in a short period of time. intravenous midazolam can also be used as a component of intravenous supplementation of nitrous oxide and oxygen (balanced anesthesia); - continuous intravenous infusion for sedation of intubated and mechanically ventilated patients as a component of anesthesia or during treatment in a critical care setting. injectable midazolam hydrochloride is contraindicated in patients with a known hypersensitivity to the drug. benzodiazepines are contraindicated in patients with acute narrow-angle glaucoma. benzodiazepines may be used in patients with open-angle glaucoma only if they are receiving appropriate therapy. measurements of intraocular pressure in patients without eye disease show a moderate lowering following induction with midazolam hydrochloride; patients with glaucoma have not been studied. midazolam hydrochloride is not intended for intrathecal or epidural administration due to the presence of the preservative benzyl alcohol in the dosage form. midazolam hydrochloride is contraindicated for use in premature infants because the formulation contains benzyl alcohol (see warnings and precautions, pediatric use ). midazolam hydrochloride contains midazolam, a schedule iv control substance. midazolam was actively self-administered in primate models used to assess the positive reinforcing effects of psychoactive drugs. midazolam produced physical dependence of a mild to moderate intensity in cynomolgus monkeys after 5 to 10 weeks of administration. available data concerning the drug abuse and dependence potential of midazolam suggest that its abuse potential is at least equivalent to that of diazepam. withdrawal symptoms, similar in character to those noted with barbiturates and alcohol (convulsions, hallucinations, tremor, abdominal and muscle cramps, vomiting and sweating), have occurred following abrupt discontinuation of benzodiazepines, including midazolam. abdominal distention, nausea, vomiting, and tachycardia are prominent symptoms of withdrawal in infants. the more severe withdrawal symptoms have usually been limited to those patients who had received excessive doses over an extended period of time. generally milder withdrawal symptoms (e.g., dysphoria and insomnia) have been reported following abrupt discontinuance of benzodiazepines taken continuously at therapeutic levels for several months. consequently, after extended therapy, abrupt discontinuation should generally be avoided and a gradual dosage tapering schedule followed. there is no consensus in the medical literature regarding tapering schedules; therefore, practitioners are advised to individualize therapy to meet patient's needs. in some case reports, patients who have had severe withdrawal reactions due to abrupt discontinuation of high-dose long-term midazolam, have been successfully weaned off of midazolam over a period of several days.